SCHEMBL1165347

SCHEMBL1165347

O=[N+]([O-])c1ccc(Br)cc1Nc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.65
TDP1 Q9NUW8 4/20 0.65
ALDH1A1 P00352 2/20 0.65
MAPK1 P28482 2/20 0.65
CASP7 P55210 1/20 0.65
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
HCAR3 P49019 1/20 0.52
HSP90AA1 P07900 1/20 0.52
MAPT P10636 4/20 0.51
IDO1 P14902 2/20 0.51
POLB P06746 1/20 0.51
MYC P01106 1/20 0.51
WNK1 Q9H4A3 1/20 0.51
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
GFER P55789 1/20 0.48
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30847370 1.00 L3MBTL1 (0.65) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL10171005 0.90 IDO1 (0.58) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL12818094 0.89 L3MBTL1 (0.51) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL337857 0.87 L3MBTL1 (0.68) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL14247759 0.84 MAPK1 (0.53) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL22191303 0.84 IDO1 (0.50) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL28334343 0.84 MEN1 (0.63) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL31144749 0.84 ALDH1A1 (0.54) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL31144798 0.84 L3MBTL1 (0.52) L3MBTL1TDP1ALDH1A1MAPK1CASP7
SCHEMBL14247885 0.84 FBP1 (0.55) L3MBTL1TDP1ALDH1A1MAPK1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015328-A1 ATM KINASE INHIBITORS EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) 2026-01-15 US disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
EP-3906233-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-31 EP disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 US disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 US disclosed
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-03 US disclosed
EP-3906028-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 EP disclosed
EP-3126371-B1 METAL COMPLEXES, COMPRISING CARBENE LIGANDS HAVING AN O-SUBSTITUTED NON-CYCLOMETALATED ARYL GROUP AND THEIR USE IN ORGANIC LIGHT EMITTING DIODES UDC IRELAND LTD (IE) 2021-11-10 EP disclosed
EP-3906233-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 EP disclosed
EP-2320897-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE Treventis Corporation (US) 2011-05-18 EP disclosed
US-20110034458-A1 PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2011-02-10 US disclosed
US-7842698-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO S.A. (CH) 2010-11-30 US disclosed
WO-2010025375-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE TREVENTIS CORPORATION (US) 2010-03-04 WO disclosed
WO-2010025375-A1 COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE TREVENTIS CORPORATION (US) 2010-03-04 WO disclosed
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-10-30 US disclosed
CN-101052640-A Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors APPLIED RESEARCH SYSTEMS (AN) 2007-10-10 CN disclosed
US-4138572-A Malonanilic derivatives ROUSSEL UCLAF (FR) 1979-02-06 US disclosed
US-4001408-A SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESSES AND COMPOSITION INCLUDING THOSE ROUSSEL-UCLAF (FR) 1977-01-04 US disclosed
US-3984398-A 1,5-Benzodiazepine-2,4-diones ROUSSEL-UCLAF (FR) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof PIK3CA, PIK3CD, PIK3CB L3MBTL1 3611/4885TDP1 1000/4885ALDH1A1 2379/4885
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors PIK3CD, PIK3CA, PIK3CB L3MBTL1 1864/4885TDP1 1663/4885ALDH1A1 1437/4885
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE MAP3K20, MAP3K1, PACSIN2 L3MBTL1 1520/4885TDP1 1084/4885ALDH1A1 4726/4885
US-20260015328-A1 ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 L3MBTL1 824/4885TDP1 265/4885ALDH1A1 4484/4885
US-20110034458-A1 PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS PIK3CD, PIK3CA, PTEN L3MBTL1 2076/4885TDP1 1722/4885ALDH1A1 1232/4885
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE CSNK1A1, MAP3K20, CSNK1G3 L3MBTL1 2284/4885TDP1 1539/4885ALDH1A1 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.